Age of Blood in Sickle Cell Transfusion -The Effects of Phosphotidylserine Expression on Older Red Cell Units in Adults With Sickle Cell Disease

About the study

The Investigators hypothesize that older red cell units trigger phagocytosis and activation of circulating macrophages with a downstream immunomodulatory cascade and release of excess Non Transferrin Bound Iron(NTBI) that leads to increased rates of infection in adults with Sickle Cell Disease(SCD).

To test this hypothesis, the study staff will perform a randomized prospective clinical trial. In aim 1, the study staff will determine the biochemical differences between ≥30 day-old versus ≤10 day-old units. In aim 2, the study staff will determine the physiologic effects of the transfused blood in a patient with SCD. Lastly, in aim 3, the study staff will explore the clinical implications of receiving older red cells over a 3 month period.

Study point of contact

David Wichlan
Matthew Karafin, MD


3 United States sites


16 Years - 60 Years


Phase 2/Phase 3

Study type






participation requirements

age 16 to 60 years
Hemoglobin SS/Hemoglobin Sβ-thalassemia^0
on chronic red cell transfusion therapy
outpatient at the time of transfusion

participation restrictions

history of reactions to transfusion therapy that cannot be adequately managed by antihistamines
≥ 2 red cell alloantibodies
participation in another therapeutic trial for SCD
HIV positive
uncontrolled inter-current illness, or psychiatric illness/social situations that would limit compliance with study requirements.


  • Atlanta, Georgia, United States, Emory University, 30322 [Recruiting]
  • Chapel Hill, North Carolina, United States, University of North Carolina at Chapel Hill, 27599 [Recruiting]
  • Milwaukee, Wisconsin, United States, Versiti Wisconsin, 53226 [Completed]
Last updated 2022-02-28